bioMérieux launches leading endocrinology testing offer dedicated to enhancing equine health

bioMérieux launches leading endocrinology testing offer dedicated to enhancing equine health

With two hormone immunoassay tests, VIDAS^® Equine ACTH and VIDAS^® Equine INSULIN, bioMérieux makes laboratory standard results achievable directly at the Point of Care. 

Marcy-l’Étoile, France – December 4^th, 2025 – bioMérieux, a world leader in the field of in vitro diagnostics, today announced the launch of its immunoassay endocrinology offer for equine health, consisting of VIDAS^® Equine INSULIN and VIDAS^® Equine ACTH. 

By providing fast and accurate test results of insulin levels in approximately 20 minutes, VIDAS^® Equine INSULIN will help with the diagnosis and effective management of Equine Metabolic Syndrome (EMS), commonly associated with insulin dysregulation in horses. VIDAS^® Equine ACTH provides dysregulation level testing of the adrenocorticotropic (ACTH) hormone related to the development ofEquine Cushing’sDisease(correctly known as Pituitary Pars Intermedia Dysfunction - PPID) in just about 45 minutes. Between 18%-27%^[1] of horses over 15 years old show symptoms related to

Cushing’s or insulin dysregulation. Those common equine endocrine disorders can increase risk for complication, especially chronic laminitis².

“Our new endocrinology tests, because of their rapidity and ease of use, will bring clinical value for veterinary practices, directly at the Point of Care. Equine Metabolic Syndrome and Cushing’s Disease are chronic conditions that often evade detection in their initial stages, making early testing crucial in achieving proper management and animal care,” explains Pierre Rouppert, Global Veterinary Product Manager at bioMérieux.

Laboratory standard hormone tests will become available in the UK at the Point of Care using bioMérieux’s VIDAS^® KUBE™ immunoanalyser, marking the first equine-focused testing platform to launch with this capability. After the launch last June of VETFIRE^TM, a cutting-edge PCR test for detecting respiratory infections in horses, bioMérieux continues to transfer its expertise in the human testing sector to veterinary practice, reducing wait times for results and enabling faster clinical decisions with the combined diagnostic power of the two VIDAS^® Equine endocrinology tests.

David Smart, Global Veterinary Business Developer at bioMérieux, says: “This dedicated equine immunoassay test for insulin and ACTH represents a transformative step forward in animal care. Veterinary practitioners will be able to achieve fast, reliable and costeffective laboratory grade results that can aid early detection and subsequent diagnosis for two prolific and debilitating medical conditions in horses. The fast and accurate results from these two new tests will allow quicker clinical decisions that will ultimately help more horses receive an improved standard of care and reassure horse owners.”

With this scientifically precise, on-demand technological innovation, bioMérieux brings to veterinary medicine its 60+ years of expertise in clinical diagnostics and continues to expand its high-quality offering to meet the needs of the fast-moving veterinary and equine sectors. The two new tests will initially be available in the United Kingdom and France, with international rollout planned in the coming months.     

-Ends-

ABOUT BIOMÉRIEUX

Pioneering Diagnostics

A world leader in the field of in vitro diagnostics since 1963, bioMérieux is present in 45 countries and serves more than 160 countries with the support of a large network of distributors. In 2024, revenues reached €4 billion, with over 93% of sales outside of France. 

bioMérieux provides diagnostic solutions (systems, reagents, software and services) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are mainly used for diagnosing infectious diseases. They are also used for detecting microorganisms in agri-food, pharmaceutical and cosmetic products.www.biomerieux.com. 

bioMérieux is listed on the Euronext Paris stock market.  Symbol: BIM – ISIN Code: FR0013280286

 Reuters: BIOX.PA/Bloomberg: BIM.FP 

CONTACTS

INVESTORS RELATIONS                                                             

bioMérieux                                                                                                

Aymeric Fichet                                                                                           

Tel: +33 (0)4 78 87 20 00                   investor.relations@biomerieux.com                           

MEDIA RELATIONS                                                                            

bioMérieux    Ireland & United Kingdom    Romain Duchez         Sarah Cawley (Hanover)         

Tel: +33 (0)4 78 87 20 00       Tel: +44 (0)7817 688031         media@biomerieux.com              scawley@hanovercomms.com